This activity was originally presented as part of the 2024 Asembia Specialty Day of Education Winter Edition.
Program Description
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition affecting the sinuses and nasal passages, leading to significant health burden. Due to the range of symptoms and associated diseases, patients with CRSwNP experience a reduced quality of life resulting from persistent symptoms. Though patients often respond to brief durations of corticosteroids for immediate and/or short-term use, medical management often fails as patients become refractory to systemic steroids. In recent years, the treatment practice has shifted toward use of biologics that target the inflammatory cytokines in CRSwNP. However, concerns about the accessibility of new biologic drugs have risen. This activity will equip specialty pharmacists to identify patients in the early stages of disease and determine if they are candidates for medical management with a biologic. Informed by social media analytic tools and insights about discussion points from patients, caregivers, and health care professionals regarding the treatment of CRSwNP gathered through artificial intelligence technology, the interactive format of this program features opportunities for faculty to debate and discuss challenges and trends in the use of biologics for CRSwNP. Participants will be able to provide responses to the discussion in real time.
Target Audience: Specialty pharmacists
Type of Activity: Application
Release date: December 19, 2024
Expiration date: December 19, 2025
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate treatment challenges associated with chronic rhinosinusitis with nasal polyps (CRSwNP)
- Explore safety and efficacy data of biologic therapy for the management of CRSwNP
- Identify opportunities for pharmacists to collaborate with other health care providers to improve access to biologic therapy for the management of CRSwNP
Ellen R. Dixon, PharmD, CSP, CHN
Coordinator of Clinical Outcomes and Patient Engagement
PANTHERx Rare Pharmacy
Pittsburgh, Pennsylvania
Damien Fisher, PharmD, AE-C
Pharmacy Clinical Practice Specialist
Co-Coordinator of LAPPE program UTMB
PGY2 Amb Care Residency Program Coordinator
Specialty: Dermatology, Allergy, Pulmonology
University of Texas Medical Branch
Galveston, Texas
Eileen Wang, MD, MPH, FAAAAI, FACAAI
Associate Professor
Division of Allergy and Clinical Immunology
National Jewish Health, Department of Medicine
University of Colorado School of Medicine
Denver, Colorado
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-358-H01-P. The activity is available for CE credit through December 19, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Eileen Wang, MD, MPH, FAAAAI, FACAAI, has the following relevant financial relationships with commercial interests to disclose:
Speakers Bureau: AstraZeneca, Genentech.
Consultant: Amgen, Apogee, AstraZeneca, GlaxoSmithKline.
Grant Support: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi.
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Ellen R. Dixon, PharmD, CSP, CHN
Damien Fisher, PharmD, AE-C
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here